格隆汇2月16日丨金斯瑞生物科技(01548.HK)公布,集团预期截至2024年12月31日止年度录得的净利润较截至2023年12月31日止年度有重大增长。集团预期净利润增长主要来自以下原因:(1)视作出售传奇生物的一次性未实现收益约32亿美元。传奇生物科技股份有限公司("传奇生物",其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)从集团解除合并,于2024年10月18日生效,其自此被重新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.